Boston Scientific stock rating reiterated at Buy by TD Cowen

TD Cowen reiterated a Buy rating and $80 price target on Boston Scientific, citing expected success of the Fracture IDE study for its Seismiq coronary intravascular lithotripsy device. The study's positive readout would support a planned U.S. launch in the first half of 2027, while the company also has a $2 billion accelerated buyback underway and a $1.5 billion investment in MiRus. The article is supportive for BSX fundamentals, but the near-term market impact is likely limited to the stock and related medtech peers.

Analysis

BSX is becoming a cleaner expression of procedural innovation with multiple shots on goal: coronary lithotripsy, buybacks, and optionality in structural heart. The market tends to underwrite these franchises as single-product stories, but the second-order effect is that successful trial readthroughs can compress the discount rate on the whole pipeline, because commercial infrastructure is already in place. That means upside can propagate beyond the named device if management proves it can keep converting clinical data into reimbursable, high-margin launches.

The more interesting wrinkle is capital allocation. A large repurchase program alongside an early-stage strategic investment creates a dual narrative of returning cash while buying call options on adjacent categories; that usually supports multiple expansion if execution remains clean, but it also raises the bar for future dilution of attention. Competitors in coronary calcium modification and TAVR likely face a longer period of price and share pressure than the headline suggests, because BSX can subsidize launch economics with a stronger balance sheet and a broader installed base.

From a timing standpoint, the near-term catalyst is binary and event-driven, but the real trade is over 6-18 months as investors mark in U.S. launch probability and adoption slope. The biggest risk is not the trial itself; it's reimbursement friction, physician switching inertia, or any delay that pushes commercialization into a window where competitors can sharpen their claims. If the readout is strong, the market may still underappreciate how quickly a $1.5B category can re-rate a large medtech name once it becomes a second growth engine.

Consensus looks mildly complacent: it treats BSX as a steady compounder, but the setup has more convexity than that implies. If the study succeeds and management sounds confident on launch cadence, the stock can grind higher for months rather than gap and fade, especially with buybacks reducing float and cushioning downside on pullbacks.

Key Decisions for Investors

• Go long BSX into the catalyst with a 3-6 month horizon; use a staggered entry before the presentation and add only if the data confirms endpoint credibility. Reward/risk favors upside re-rating if launch probability rises, while downside is partially supported by repurchase flow.
• For defined risk, buy BSX call spreads 3-9 months out rather than outright calls; this captures post-readout drift without overpaying for implied volatility. Best structure: slightly out-of-the-money spreads sized for a 2:1 to 3:1 payoff.
• Pair trade: long BSX / short a smaller coronary calcium-modification or structural-heart competitor with less balance-sheet flexibility over the next 1-2 quarters. The thesis is that BSX can fund adoption and defend pricing better than niche peers if the category expands.
• If BSX rallies sharply on the event, take partial profits on day 1-3 and keep a core position for the 6-12 month commercialization inflection. The market often overreacts to the headline but underprices the revenue conversion lag.
• Avoid chasing if the stock gaps up hard pre-market; wait for post-event consolidation and re-enter on the first 2-4% pullback unless management commentary materially weakens the launch timeline.